telmisartan has been researched along with Erectile Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumhäkel, M; Böhm, M; Dagenais, GR; Diaz, R; Gao, P; Jansky, P; Jennings, GL; Liu, L; Mann, JF; Probstfield, J; Sleight, P; Teo, K; Yusuf, S | 1 |
| Baumhäkel, M; Böhm, M; Kratz, M; Schlimmer, N | 1 |
| Baumhäkel, M; Böhm, M; Koon, T; Probstfield, JL; Schmieder, R; Yusuf, S; Zhao, F | 1 |
2 trial(s) available for telmisartan and Erectile Dysfunction
| Article | Year |
|---|---|
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoler
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Mortality; Predictive Value of Tests; Ramipril; Telmisartan; Treatment Outcome | 2010 |
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Erectile Dysfunction; Global Health; Humans; Male; Middle Aged; Multivariate Analysis; Patient Satisfaction; Prospective Studies; Ramipril; Risk Factors; Telmisartan | 2007 |
1 other study(ies) available for telmisartan and Erectile Dysfunction
| Article | Year |
|---|---|
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cholesterol; Drug Therapy, Combination; Endothelium, Vascular; Erectile Dysfunction; Free Radicals; Lipid Peroxides; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Ramipril; Renin-Angiotensin System; Telmisartan | 2011 |